Analyst: St. Jude Medical's Riata Ruckus Won't Hurt CRM Market Long-term

The headline-grabbing hullaballou over St. Jude's Medical's recalled Riata leads last week won't do any lasting damage to the overall cardiac rhythm management market, according to Barclays Capital analyst Adam Feinstein; also, Zoll's LifeVest operation growing at a 73% clip; Osprey Medical's Australian IPO brings in $21M; Edwards Lifesciences tumbles, recovers from JP Morgan downgrade; Conceptus scores FDA nod for Essure data; Cardinal Health, Carestream, Cogito win gov't contracts; plus, a Funding ROundup and analysts' ups and downs.